CL2007002225A1 - Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un - Google Patents
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de unInfo
- Publication number
- CL2007002225A1 CL2007002225A1 CL200702225A CL2007002225A CL2007002225A1 CL 2007002225 A1 CL2007002225 A1 CL 2007002225A1 CL 200702225 A CL200702225 A CL 200702225A CL 2007002225 A CL2007002225 A CL 2007002225A CL 2007002225 A1 CL2007002225 A1 CL 2007002225A1
- Authority
- CL
- Chile
- Prior art keywords
- agent
- conjugado
- codifies
- pdgfr
- guests
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83564706P | 2006-08-03 | 2006-08-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2007002225A1 true CL2007002225A1 (es) | 2008-04-18 |
Family
ID=39146823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL200702225A CL2007002225A1 (es) | 2006-08-03 | 2007-07-31 | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
Country Status (24)
Country | Link |
---|---|
US (3) | US20090324601A1 (es) |
EP (3) | EP2420513A1 (es) |
JP (1) | JP5437804B2 (es) |
KR (1) | KR101531422B1 (es) |
CN (2) | CN103588881A (es) |
AR (1) | AR062268A1 (es) |
AU (1) | AU2007348940B2 (es) |
BR (1) | BRPI0715223A2 (es) |
CA (1) | CA2657898A1 (es) |
CL (1) | CL2007002225A1 (es) |
DK (1) | DK2049571T3 (es) |
ES (1) | ES2402380T3 (es) |
HK (1) | HK1128481A1 (es) |
IL (2) | IL196209A (es) |
MX (2) | MX2009001021A (es) |
NO (1) | NO20090069L (es) |
NZ (2) | NZ575245A (es) |
PL (1) | PL2049571T3 (es) |
PT (1) | PT2049571E (es) |
SI (1) | SI2049571T1 (es) |
TW (1) | TWI503329B (es) |
UY (1) | UY30525A1 (es) |
WO (1) | WO2008112003A2 (es) |
ZA (1) | ZA200900461B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CL2007002225A1 (es) * | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
EP2559771A3 (en) * | 2007-05-17 | 2013-06-12 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators |
EP2257571B1 (en) * | 2008-03-10 | 2015-03-04 | Theraclone Sciences, Inc. | Compositions and methods for the therapy and diagnosis of cytomegalovirus infections |
JP2013177317A (ja) * | 2010-06-24 | 2013-09-09 | Meneki Seibutsu Kenkyusho:Kk | 抗pdgf受容体抗体 |
WO2012003470A2 (en) * | 2010-07-02 | 2012-01-05 | Medimmune, Llc | Antibody formulations |
US9428565B2 (en) | 2011-01-31 | 2016-08-30 | The General Hospital Corporation | Treatment and bioluminescent visualization using multimodal TRAIL molecules |
AU2012328173B2 (en) * | 2011-10-28 | 2016-04-21 | Janssen Biotech, Inc. | Therapeutic agents and uses thereof |
EP2814509B1 (en) * | 2012-02-17 | 2018-05-16 | Seattle Genetics, Inc. | Antibodies to integrin v 6 and use of same to treat cancer |
NZ724395A (en) * | 2012-04-24 | 2018-03-23 | Thrombogenics Nv | Anti-pdgf-c antibodies |
US9862932B2 (en) | 2012-07-24 | 2018-01-09 | The General Hospital Corporation | Oncolytic virus therapy for resistant tumors |
US9605074B2 (en) * | 2012-08-30 | 2017-03-28 | The General Hospital Corporation | Multifunctional nanobodies for treating cancer |
BR112015010722A2 (pt) * | 2012-11-09 | 2017-08-22 | Pfizer | Anticorpos específicos de fator de crescimento derivado de plaquetas de isoforma b e composições e usos dos mesmos |
GB201318793D0 (en) * | 2013-10-24 | 2013-12-11 | Plaquetec Ltd | Vascular Biomarkers |
PT3071595T (pt) | 2013-11-19 | 2019-06-11 | Fredax Ab | Anticorpo anti calicreína-2 humanizado |
MX2018001644A (es) * | 2015-08-11 | 2018-11-09 | Wuxi Biologics Cayman Inc | Anticuerpos anti-pd-1 novedosos. |
CN109134655B (zh) * | 2018-11-28 | 2019-02-26 | 上海复宏汉霖生物技术股份有限公司 | 一种抗PDGFRα的单克隆抗体及其制备方法和应用 |
KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
Family Cites Families (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3180193A (en) | 1963-02-25 | 1965-04-27 | Benedict David | Machines for cutting lengths of strip material |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
DE3169595D1 (en) | 1980-11-10 | 1985-05-02 | Gersonde Klaus | Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
JPS58118008A (ja) | 1982-01-06 | 1983-07-13 | Nec Corp | デ−タ処理装置 |
EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
JPS58166633A (ja) | 1982-03-29 | 1983-10-01 | Toshiba Corp | 有機溶媒電池用正極 |
JPS58166634A (ja) | 1982-03-29 | 1983-10-01 | Toshiba Corp | 有機溶媒電池用正極 |
DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
US4615885A (en) | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
JPS62170639A (ja) | 1986-01-22 | 1987-07-27 | 株式会社システムメンテナンス | 防蟻板の取付け工法 |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
ATE179457T1 (de) | 1989-02-09 | 1999-05-15 | Us Health | Zuwachsfaktorrezeptorgen deriviert von platten des typs oc |
US5468468A (en) * | 1989-02-09 | 1995-11-21 | The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services | Method for making a monoclonal antibody, monoclonal antibodies to α PD |
JP3070763B2 (ja) | 1989-08-09 | 2000-07-31 | ロメッド インコーポレイティド | テクネチウムまたはレニウムでの抗体または他のタンパク質の直接放射能標識 |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
CA2050918A1 (en) | 1990-01-12 | 1991-07-13 | Raju Kucherlapati | Generation of xenogeneic antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
FR2664073A1 (fr) | 1990-06-29 | 1992-01-03 | Thomson Csf | Moyens de marquage d'objets, procede de realisation et dispositif de lecture. |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
WO1992003917A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International | Homologous recombination in mammalian cells |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
DK0584082T3 (da) * | 1991-01-31 | 2000-10-16 | Univ California | Domæner i den ekstracellulære region af humane blodpladeafledte vækstfaktorreceptorpolypeptider |
IE920318A1 (en) | 1991-01-31 | 1992-07-29 | Univ California | Human platelet-derived growth factor receptors |
WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
US5444151A (en) | 1992-05-15 | 1995-08-22 | Ludwig Institute For Cancer Research | Platelet derived growth factor antagonists |
CA2135313A1 (en) | 1992-06-18 | 1994-01-06 | Theodore Choi | Methods for producing transgenic non-human animals harboring a yeast artificial chromosome |
ATE381614T1 (de) | 1992-07-24 | 2008-01-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
US5981175A (en) | 1993-01-07 | 1999-11-09 | Genpharm Internation, Inc. | Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
EP1916300A1 (en) | 1995-08-29 | 2008-04-30 | Kirin Pharma Kabushiki Kaisha | Chimeric animal and method for producing the same |
IT1278764B1 (it) | 1995-10-03 | 1997-11-27 | Volta Ind Srl | Pila a secco con catodo additivato |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
CZ291386B6 (cs) | 1996-02-13 | 2003-02-12 | Zeneca Limited | Chinazolinové deriváty jako inhibitory VEGF, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje |
US6291455B1 (en) | 1996-03-05 | 2001-09-18 | Zeneca Limited | 4-anilinoquinazoline derivatives |
AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US5882644A (en) * | 1996-03-22 | 1999-03-16 | Protein Design Labs, Inc. | Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
ATE549918T1 (de) | 1996-12-03 | 2012-04-15 | Amgen Fremont Inc | Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden |
DE69837529T2 (de) | 1997-02-12 | 2007-07-26 | Electrophoretics Ltd., Cobham | Proteinmarker für lungenkrebs und deren verwendung |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
KR20010075108A (ko) * | 1998-09-14 | 2001-08-09 | 라즈 외스테르가아드 페데르센 | 기능적 면역글로불린 수퍼패밀리 단백질을 생산하는 방법 |
ATE439592T1 (de) | 1998-12-10 | 2009-08-15 | Bristol Myers Squibb Co | Proteingerüste für antikörper-nachahmer und andere bindende proteine |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
PL205557B1 (pl) | 1999-02-10 | 2010-05-31 | Astrazeneca Ab | Pochodne indolu |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
NZ518028A (en) | 1999-11-05 | 2004-03-26 | Astrazeneca Ab | Quinazoline derivatives as VEGF inhibitors |
ME00415B (me) | 2000-02-15 | 2011-10-10 | Pharmacia & Upjohn Co Llc | Pirol supstituisani 2-indol protein kinazni inhibitori |
US20030165831A1 (en) | 2000-03-21 | 2003-09-04 | John Lee | Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer |
CN1431999A (zh) | 2000-05-31 | 2003-07-23 | 阿斯特拉曾尼卡有限公司 | 具有血管损伤活性的吲哚衍生物 |
UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
EP1301498A1 (en) | 2000-07-07 | 2003-04-16 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as angiogenesis inhibitors |
US20050277627A1 (en) | 2000-07-07 | 2005-12-15 | Arnould Jean C | Colchinol derivatives as vascular damaging agents |
EP2357187A1 (en) | 2000-12-12 | 2011-08-17 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
US20050058649A1 (en) * | 2002-12-02 | 2005-03-17 | Landes Gregory M. | Antibodies directed to phospholipase A2 and uses thereof |
SI1648998T1 (sl) * | 2003-07-18 | 2015-01-30 | Amgen Inc. | Specifiäťna vezavna sredstva na hepatocitni rastni faktor |
AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
JP4712724B2 (ja) * | 2003-12-23 | 2011-06-29 | クルセル ホランド ベー ヴェー | CD1aに対するヒト結合分子 |
WO2005087269A1 (ja) * | 2004-03-16 | 2005-09-22 | Dnavec Research Inc. | 腫瘍増殖を抑制する方法 |
CA2678008C (en) | 2005-06-17 | 2013-07-30 | Imclone Systems Incorporated | Methods of treating a secondary bone tumor with anti-pdgfralpha antibodies |
CL2007002225A1 (es) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
JP6071725B2 (ja) | 2013-04-23 | 2017-02-01 | カルソニックカンセイ株式会社 | 電気自動車の駆動力制御装置 |
US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
US11284893B2 (en) | 2019-04-02 | 2022-03-29 | Covidien Lp | Stapling device with articulating tool assembly |
-
2007
- 2007-07-31 CL CL200702225A patent/CL2007002225A1/es unknown
- 2007-08-02 WO PCT/US2007/075117 patent/WO2008112003A2/en active Application Filing
- 2007-08-02 ES ES07873957T patent/ES2402380T3/es active Active
- 2007-08-02 KR KR1020097002482A patent/KR101531422B1/ko not_active IP Right Cessation
- 2007-08-02 EP EP11171219A patent/EP2420513A1/en not_active Withdrawn
- 2007-08-02 EP EP11171222A patent/EP2420514A1/en not_active Withdrawn
- 2007-08-02 CN CN201310499975.9A patent/CN103588881A/zh active Pending
- 2007-08-02 PL PL07873957T patent/PL2049571T3/pl unknown
- 2007-08-02 CA CA002657898A patent/CA2657898A1/en not_active Abandoned
- 2007-08-02 DK DK07873957.0T patent/DK2049571T3/da active
- 2007-08-02 NZ NZ575245A patent/NZ575245A/xx not_active IP Right Cessation
- 2007-08-02 NZ NZ596381A patent/NZ596381A/xx not_active IP Right Cessation
- 2007-08-02 US US12/376,052 patent/US20090324601A1/en not_active Abandoned
- 2007-08-02 BR BRPI0715223-0A2A patent/BRPI0715223A2/pt not_active IP Right Cessation
- 2007-08-02 AU AU2007348940A patent/AU2007348940B2/en not_active Ceased
- 2007-08-02 SI SI200731189T patent/SI2049571T1/sl unknown
- 2007-08-02 PT PT78739570T patent/PT2049571E/pt unknown
- 2007-08-02 EP EP07873957A patent/EP2049571B1/en not_active Not-in-force
- 2007-08-02 CN CN2007800281018A patent/CN101558082B/zh not_active Expired - Fee Related
- 2007-08-02 MX MX2009001021A patent/MX2009001021A/es active IP Right Grant
- 2007-08-02 TW TW096128380A patent/TWI503329B/zh not_active IP Right Cessation
- 2007-08-02 JP JP2009523063A patent/JP5437804B2/ja not_active Expired - Fee Related
- 2007-08-03 US US11/833,473 patent/US7754859B2/en not_active Expired - Fee Related
- 2007-08-03 AR ARP070103450A patent/AR062268A1/es unknown
- 2007-08-03 UY UY30525A patent/UY30525A1/es not_active Application Discontinuation
-
2008
- 2008-12-25 IL IL196209A patent/IL196209A/en not_active IP Right Cessation
-
2009
- 2009-01-06 NO NO20090069A patent/NO20090069L/no not_active Application Discontinuation
- 2009-01-20 ZA ZA2009/00461A patent/ZA200900461B/en unknown
- 2009-07-09 HK HK09106174.6A patent/HK1128481A1/xx not_active IP Right Cessation
-
2010
- 2010-02-18 US US12/708,022 patent/US8697664B2/en not_active Expired - Fee Related
-
2011
- 2011-09-09 MX MX2011009563A patent/MX2011009563A/es unknown
-
2012
- 2012-11-01 IL IL222833A patent/IL222833A0/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2007002225A1 (es) | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un | |
IL283424A (en) | Stabilized formulations that include antibodies against the interleukin receptor (IL-4R) | |
BRPI0916964A2 (pt) | polipetídeo, anticorpo, ácido nucléico, vetor, célula hospedeira, método para produzir um polipeptídeo, composição e uso do polipeptídeo | |
CL2008001128A1 (es) | Asparraginasa; secuencia de acido nucleico que la codifica; construccion de acidos nucleicos, vector y celula huesped; metodo para producir asparraginasa; composicion que comprende variante; uso de la variante de asparraginasa; proceso de elaboracion | |
BRPI1007448A2 (pt) | catalisador com distribuição bimodal de tamanho de poros e uso do mesmo | |
BRPI0905712A2 (pt) | "conjunto de células de bateria e método para construção do conjunto de células de bateria" | |
CL2007002835A1 (es) | Anticuerpo monoclonal especifico para el receptor cxcr4; acido nucleico que lo codifica; vector y celula que lo comprenden; metodo de produccion; inmunoconjugado y composicion que lo comprende; y su uso para tratar cancer, trastornos inflamatorios y | |
Chan et al. | Chemical synthesis and biological evaluation of the englerin analogues | |
EP2138926A4 (en) | METHOD FOR DETERMINING THE TARGET OF A REQUIREMENT AND PROCESS AND DISPLAY SYSTEM USING THE PROCESS | |
BRPI1011886A2 (pt) | solução contendo ácido hiplocloroso e métodos do uso do mesmo. | |
CL2012002464A1 (es) | Proceso para la preparación de compuestos pesticidas que contienen un grupo tio-triazolo, que comprende hacer reaccionar un compuesto triazolo con un reactivo de grignard; compuestos pesticidas que contienen un grupo tio-triazolo; y su uso. | |
EP2246315A4 (en) | CEMENT MIXTURE AND CEMENT COMPOSITION AND CONCRETE CONTAINING CEMENT MIXTURE | |
IL210787A0 (en) | Methods for the cytological analysis of cervical cells | |
WO2012031280A3 (en) | Identification and enrichment of cell subpopulations | |
BRPI0907663A8 (pt) | composição que compreende hfo- 123 yf, composição que compreende hcfc-243db, composição que compreende hcfo- 1233xf, composição que comproeende hcfc- 244bb, uso das composições e método de uso das composições | |
BRPI0822104A2 (pt) | Composições antimicrobianas e métodos para o uso das mesmas | |
EP2172542A4 (en) | METHOD FOR CONSTRUCTING A MASS FROM MYOCARDIAL CELLS AND USE OF THE MASS FROM MYOCARDIAL CELLS | |
BR112012027147A2 (pt) | método in vitro destinado à liberação de um composto de vitamina d e à medição de um composto de vitamina d, composição e mistura de reagente, uso de uma composição de reagente e kits | |
IL201374A0 (en) | Alcohol alkoxylates, agents containing these, and use of the alcohol alkoxylates as adjuvants for the agrochemical field | |
PL392881A1 (pl) | Sposoby i instalacje do mieszania wsadu reaktora | |
IL196375A0 (en) | Compositions for decontaminating hazardous chemical and biological compounds, methods employing same and systems for preparing same | |
BR112013005071A2 (pt) | ligante de cimento, concreto e uso de ligante de cimento | |
BRPI1006782A2 (pt) | composição, mistura polimerizável, artigo, método de uso do artigo e métodos para fabricar um suporte hidrofobicamente derivatizado | |
BR112013007230A2 (pt) | ''processo de cristalização pulverizável,particulas sólidas e uso''. | |
EP2150926A4 (en) | PLANNING SYSTEMS AND METHODS FOR BUILDING RESOURCES |